Every Form 4 that Aclaris Therapeutics, Inc. (ACRS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ACRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACRS filings page.
Aclaris Therapeutics, Inc. reports that Chief Scientific Officer Roland Kolbeck had 36,375 restricted stock units vest and convert into an equal number of common shares on August 1, 2026. Of these, 12,385 shares were withheld by the company at $5.20 per share to satisfy tax withholding obligations. Following the transactions, Kolbeck retains 109,125 restricted stock units, which vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, conditioned on continued service.
Aclaris Therapeutics director Anand Mehra reported routine equity compensation activity. On June 4, 2026, he received 10,987 restricted stock units and a stock option for 42,350 shares of common stock at an exercise price of $4.71 per share, both granted at no cash cost.
The option vests in twelve equal monthly installments starting on July 4, 2026, while the 10,987 restricted stock units are scheduled to vest on June 4, 2027, subject to his continuous service. On June 5, 2026, 11,580 previously granted restricted stock units vested and were exercised into 11,580 shares of common stock, bringing his direct common stock holdings to 726,403 shares.
Aclaris Therapeutics director Andrew N. Schiff reported routine equity compensation and an RSU vesting and conversion. On June 5, 2026, 11,580 restricted stock units vested and were converted into 11,580 shares of common stock, bringing his directly held common shares to 25,540.
On June 4, 2026, he received 10,987 new restricted stock units and a stock option for 42,350 shares at an exercise price of $4.71 per share, both granted under company equity plans. The option vests in twelve equal monthly installments starting July 4, 2026, and the new RSUs vest on June 4, 2027, subject to continuous service.
A separate indirect position of 434,455 common shares is held by Aisling Capital IV LP and related entities, over which Aisling GP, Aisling Partners, and their managers share voting and dispositive power. Dr. Schiff disclaims beneficial ownership of these Aisling-held shares except to the extent of his pecuniary interest.
Aclaris Therapeutics director Christopher P. Molineaux reported routine equity compensation activity. On June 4, 2026, he received 10,987 restricted stock units and 42,350 stock options with an exercise price of $4.71 per share. On June 5, 2026, 11,580 previously granted RSUs vested and converted into common stock, bringing his direct common share holdings to 69,536.
Humphries William D. reported acquisition or exercise transactions in this Form 4 filing.
Aclaris Therapeutics director William D. Humphries reported equity compensation activity. On June 4, 2026, he received grants of 10,987 restricted stock units and 42,350 stock options, each option exercisable at $4.71 per share. The RSUs vest in a single installment on June 4, 2027, and the options vest in twelve equal monthly installments starting July 4, 2026, subject to continuous service.
On June 5, 2026, 11,580 previously granted restricted stock units vested and were settled into 11,580 shares of common stock. Following these transactions, Humphries directly held 45,105 shares of Aclaris common stock, reflecting routine director compensation rather than open-market buying or selling.
Aclaris Therapeutics director Vincent Milano reported equity compensation activity. On June 5, 2026, 11,580 restricted stock units vested and were settled into the same number of common shares, bringing his direct common stock holdings to 28,896 shares.
On June 4, 2026, he received 10,987 new restricted stock units that are scheduled to vest in one installment on June 4, 2027, and a grant of 42,350 stock options with a $4.71 exercise price, vesting in twelve equal monthly installments starting July 4, 2026, under Aclaris’s non-employee director compensation policy and 2025 Equity Incentive Plan.
Aclaris Therapeutics director Maxine Gowen reported equity compensation activity and an RSU vesting. On June 4, 2026, she received 10,987 Restricted Stock Units, each representing a right to one share of common stock, and a stock option for 42,350 shares at an exercise price of $4.71 per share. The option vests in twelve equal monthly installments starting July 4, 2026 under the company’s 2025 Equity Incentive Plan and non‑employee director compensation policy. On June 5, 2026, 11,580 RSUs vested and were converted into common stock at no cash cost, leaving Gowen with 33,334 common shares held directly. The filing shows awards and an RSU vesting, with no open‑market purchases or sales.
Aclaris Therapeutics, Inc. Chief Medical Officer Jesse Wayne Hall reported routine equity compensation activity involving restricted stock units (RSUs). On May 1, 2026, RSUs covering 36,375 shares were converted into common stock at a stated price of $0.00 per share, reflecting a vesting event rather than a market purchase.
On the same date, 9,330 common shares were withheld by Aclaris to cover Hall’s tax withholding obligations tied to the RSU vesting, a non‑market disposition classified as a tax-withholding transaction. After these events, Hall directly held 27,045 shares of common stock and 109,125 RSUs.
Each RSU represents a contingent right to receive one share of Aclaris common stock. The underlying RSUs vest in four equal installments on the first, second, third, and fourth anniversaries of May 1, 2025, subject to Hall’s continued service under the company’s 2024 Inducement Plan.
Aclaris Therapeutics, Inc. insider-related entity executes open-market sale. On behalf of BML Investment Partners, L.P., a fund associated with ten percent owner Michael Leonard, 300,000 shares of Aclaris common stock were sold in an open-market transaction at $4.53 per share. Following this sale, the fund’s indirect holdings reported as beneficially owned by Mr. Leonard totaled 13,950,000 shares, which he reports with a disclaimer of beneficial ownership except to the extent of his pecuniary interest.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported equity compensation-related transactions on March 1, 2026. He exercised 2,375 Restricted Stock Units, which converted into 2,375 shares of common stock at a price of $0.0000 per share. Each restricted stock unit represents a contingent right to receive one share of common stock of the company.
To cover tax withholding obligations tied to the vesting and settlement of these units, 677 shares of common stock were withheld and disposed of at $2.87 per share, as indicated by transaction code F for tax-withholding disposition. After these transactions, Balthaser directly owned 187,453 shares of common stock.
Aclaris Therapeutics CEO and director Walker Neal reported new equity awards granted on February 2, 2026. He received 274,800 restricted stock units, each representing the right to receive one share of common stock, and an employee stock option covering 961,700 shares of common stock.
The restricted stock units vest in four equal installments on the first, second, third, and fourth anniversaries of February 2, 2026, contingent on his continued service. The stock option, with a $3.61 exercise price per share, is exercisable as it vests over the same four-year schedule, also subject to continuous service.
Aclaris Therapeutics reported new equity awards to President and COO Hugh M. Davis, who also serves as a director. On February 2, 2026, he received 96,100 restricted stock units, each representing one share of common stock, and 336,300 employee stock options with a $3.61 exercise price.
The restricted stock units vest in four equal annual installments on the first through fourth anniversaries of February 2, 2026, contingent on his continuous service. The stock options become exercisable as 25% of the shares vest in four equal annual installments on the same anniversary dates, also subject to continuous service.
Aclaris Therapeutics reported an equity compensation grant to its Chief Scientific Officer, Roland Wilhelm Kolbeck, effective February 2, 2026. He received 95,700 restricted stock units, each representing one share of common stock, and an option to purchase 334,900 shares of common stock at an exercise price of $3.61 per share.
The restricted stock units vest in four equal installments on the first through fourth anniversaries of February 2, 2026, conditioned on his continued service. The stock option becomes exercisable as to 25% of the shares on each of the first, second, third, and fourth anniversaries of February 2, 2026, also subject to continuous service.
Aclaris Therapeutics granted its Chief Medical Officer, Jesse Wayne Hall, new equity awards on February 2, 2026. The awards consist of 98,100 restricted stock units, each representing one share of common stock, and an option to purchase 343,300 shares of common stock at an exercise price of $3.61 per share.
Both the restricted stock units and the stock options vest in four equal annual installments on the first, second, third and fourth anniversaries of February 2, 2026, conditioned on Hall’s continued service with the company. Following these grants, Hall directly holds the full reported amounts of these derivative securities.
Aclaris Therapeutics’ Chief Business Officer James Loerop received new equity awards dated February 2, 2026. He was granted 97,700 restricted stock units, each representing one future share of common stock, and 341,900 employee stock options with a $3.61 exercise price.
The RSUs vest in four equal annual installments on the first through fourth anniversaries of February 2, 2026, contingent on continued service. The stock options also vest in four equal annual installments over the same schedule, becoming exercisable as service-based vesting conditions are met.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported new equity awards. On February 2, 2026, he received 99,100 restricted stock units, each representing one share of Aclaris common stock. These RSUs vest in four equal annual installments starting on the first anniversary of February 2, 2026, conditioned on his continued service.
He was also granted an employee stock option for 346,800 shares of common stock at an exercise price of $3.61 per share. The option becomes exercisable as 25% of the shares vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 2, 2026, also subject to continued service.
Aclaris Therapeutics Chief Business Officer James Loerop reported routine equity compensation activity. On February 3, 2026, 20,875 restricted stock units were converted into an equal number of Aclaris common shares. Each restricted stock unit represents the right to receive one share of common stock.
To cover tax withholding on this vesting, the issuer withheld 5,937 common shares at $3.47 per share, reported under transaction code F. After these transactions, Loerop directly owned 192,260 shares of common stock and 62,625 restricted stock units, which continue to vest in four equal installments on the first four anniversaries of February 3, 2025, subject to continuous service.
Aclaris Therapeutics CEO Walker Neal reported equity compensation activity involving restricted stock units and common stock. On February 3, 2026, 63,475 restricted stock units were converted into 63,475 shares of common stock at an exercise price of $0.
To cover tax withholding related to this vesting, 18,611 shares of common stock were withheld by the company at a price of $3.47 per share. After these transactions, Neal directly owned 1,543,886 shares of common stock and 190,425 restricted stock units, which vest in four equal annual installments starting on February 3, 2025, subject to continuous service.
Aclaris Therapeutics President and COO Hugh M. Davis reported an equity compensation transaction involving restricted stock units (RSUs). On February 3, 2026, 18,675 RSUs converted into 18,675 shares of Aclaris Therapeutics common stock at an exercise price of $0 per share.
After this transaction, Davis directly owned 45,425 shares of common stock and 56,025 RSUs. Each RSU represents the right to receive one share of common stock. The RSUs underlying this transaction vest in four equal annual installments on the first through fourth anniversaries of February 3, 2025, subject to his continuous service.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported routine equity compensation activity. On February 3, 2026, 22,025 restricted stock units converted into an equal number of common shares at an exercise price of $0. To cover tax withholding on this vesting, 6,449 common shares were withheld by the company at $3.47 per share.
After these transactions, Balthaser directly owned 185,755 shares of common stock and 66,075 restricted stock units, which continue to vest in four equal annual installments starting from February 3, 2025, contingent on his continued service.
Aclaris Therapeutics, Inc.'s Chief Business Officer reported multiple equity compensation events on February 1, 2026. Several restricted stock unit (RSU) awards were exercised (transaction code M), delivering 11,250, 7,500, and 14,750 shares of common stock in separate transactions.
The filing also reports a transaction coded F, where 10,686 shares were withheld at $3.51 per share to cover tax obligations tied to RSU vesting. The RSU grants vest in four equal annual installments starting on February 1 of 2022, 2023, and 2024, subject to continued service. This amendment corrects a prior filing that mistakenly referenced a February 1, 2025 transaction due to a filing platform error.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported routine equity compensation activity involving restricted stock units and common stock. On February 1, 2026, 14,750 restricted stock units were converted into an equal number of shares of Aclaris common stock, reflecting previously granted equity awards.
To cover related tax withholding on this vesting, the issuer withheld 4,984 shares of common stock at $3.51 per share. Following these transactions, Balthaser directly held 170,179 shares of common stock and 29,500 restricted stock units. The remaining restricted stock units vest in four equal annual installments beginning on the first anniversary of February 1, 2024, contingent on his continued service.
Aclaris Therapeutics Chief Business Officer James Loerop reported an automatic share withholding related to equity compensation. On February 1, 2025, the issuer withheld 15,980 shares of common stock at $2.48 per share to cover his tax obligations upon restricted stock unit vesting.
After this transaction, Loerop beneficially owned 102,773 shares of Aclaris common stock in direct ownership. The filing is an amendment that corrects the previously reported number of shares withheld, which will change the reported beneficial ownership amounts in later filings.
Aclaris Therapeutics’ chief business officer filed an amended insider share report to correct how many shares were withheld for taxes on vested restricted stock units. On 02/01/2025, the company withheld 15,980 shares of common stock at $2.48 per share to cover tax obligations. After this correction, the officer directly held 102,773 shares of Aclaris common stock. The amendment clarifies the prior disclosure and will adjust reported beneficial ownership in future filings.